Big Pharma Split Corp.

Management Report of Fund Performance

December 31, 2024

Big Pharma Split Corp.

PRESIDENT'S MESSAGE

Unitholder Letter March 2025

Dear Valued Investor,

Thank you for placing your trust and confidence in Harvest's investment products through 2024. Harvest ETFs invests in strong, industry-leading companies, and in secular trends. That philosophy has held strong in our ETFs and funds through the past year. We will remain committed to this philosophy going forward.

In 2024, Harvest Portfolios Group Inc. celebrated its 15th year in business. On October 23, 2009, we launched our first income-oriented equity fund – The Harvest Banks & Buildings Income Fund. It was a market traded closed-end fund at the time. Banks and REITs offered some exceptional yields at the tail end of the financial crisis. This would form the basis of Harvest's first monthly income fund. Today, it is a small mutual fund but has a steady 15-year track record of consistent monthly income.

Our company has been a steadfast equity investor. Back in late September of 2023, we expanded into the fixed income space launching two fixed income covered call ETFs that provided exposure to high-quality treasury securities, which have done well with investors. Our focus as an equity investor is grounded in taking advantage of the long-term growth in capital markets, major industries, and the growth of well-positioned and managed companies. Using our finely tuned and time-tested covered call option writing strategy we aim to generate predictable, consistent, and high levels of income for unitholders in both our Equity Income and Fixed Income ETFs.

2024 saw long-term bond rates rise more than expected due to U.S. inflationary pressures. The biggest takeaway over the past year is that expectations can change quickly and significantly over a relatively short period of time in the market. For Harvest covered call treasury ETFs, large movements in the yield curve have been challenging as the funds have longer duration exposure. However, Harvest's approach reiterates that the consistent cash flow is a critical component when bond markets are volatile. This can provide a tactical advantage during times of extreme rate movements, as portfolio managers can write more options, or less options, depending on market dynamics.

Equity markets shined through 2024, finishing in the black for the second year in a row with a 20% upward movement. That was despite a negative December 2024, where the market was impacted by many factors, including tax loss selling and policy rhetoric.

In 2024 we added yet another new category to our product lineup with the launch of Harvest High Income Shares ETFs. High Income Shares ETFs are single stock ETFs that offer exposure to top U.S. companies. These ETFs are overlayed with an active covered call strategy and seek to generate high levels of monthly income.

Harvest ETFs was again honoured the LSEG Lipper Funds Awards Canada 2024 Winner, Harvest Tech Achievers Growth & Income ETF as Best Sector Equity Fund Over 5 Years (Class U) and Best Sector Equity Fund Over 3 Years (Class B). This is the third year in a row as winner of this award. This ETF also announced the 5th and 6th distribution increase in its history.

Today, Harvest manages $5.5 billion for Canadian investors across 45 ETF strategies with most of our products still built on long-term equity mandates with steady monthly income where we have now paid over $1 billion of income to unitholders. We have built a 15-year pedigree of quality and award-winning products for Canadian investors and are proud of our track record.

Moving ahead to 2025, we remain steadfast to our philosophy of choosing long-term growth industries or mega-trends. Our outlook on these industries is framed by our orientation towards high quality companies and long-term trends.

Thank you again for your support and confidence in the Harvest team and our products. We will remain dedicated in our management and development of innovative and income generating products for many years to come.

Sincerely,

Signed "Michael Kovacs"

Michael Kovacs,

President and Chief Executive Officer

Big Pharma Split Corp.

CORPORATE OVERVIEW

Harvest Portfolios Group Inc. ("Harvest" or the "Manager") is a Canadian Investment Manager founded in 2009. Harvest is focused on developing investment products that follow three investment criteria.

We (i) endeavor to develop investment products that are clear in their mandate and easy for investors to understand, (ii) strive to be transparent so that our investors can review their financial reports and know exactly what they own and (iii) seek to provide investors with consistent monthly or quarterly income by investing the fund portfolios in well managed companies that have a steady cash flow and dividend-paying history.

MANAGEMENT DISCUSSION OF FUND PERFORMANCE

The annual management report of fund performance contains financial highlights but does not contain the complete annual financial statements of the Big Pharma Split Corp. (the"Company" or "Fund"). You can get a copy of the annual financial statements at your request, and at no cost, by calling toll free at 1-866-998-8298; by writing to us at Harvest ETFs, 610 Chartwell Rd, Suite 204, Oakville, Ontario, L6J 4A5; or by visiting our website at **www.harvestetfs.com**; or on SEDAR+ at **www.sedarplus.ca**.

Unitholders may also contact us using one of these methods to request a copy of the Fund's proxy voting policies and procedures, proxy voting disclosure record, or quarterly portfolio disclosure.

INVESTMENT OBJECTIVES AND STRATEGY

The Fund invests, with equal weighting as a percentage of net asset value of the Fund, in equity securities of ten issuers, primarily from the pharmaceutical sector and that have the largest market capitalization, with the objectives of providing:

(i) holders of Preferred shares a fixed cumulative preferential quarterly cash distributions in the amount of $0.125 per Preferred share ($0.50 per annum or 5.0% per annum on the issue price of $10.00 per Preferred share) until December 31, 2027 (the "Maturity Date") and to return the original issue price of $10.00 to holders on the Maturity Date.

(ii) holders of Class A shares a regular monthly noncumulative cash distributions targeted to be $0.1031 per Class A share representing a yield on the issue price of the Class A shares of 8.25% per annum on the issue price of $15.00 per Class A Share and to provide holders with the opportunity for growth in the net asset value per Class A share.

The Fund is reconstituted and rebalanced quarterly to include issuers that: (i) are listed on a North American exchange; (ii) pay a dividend; and (iii) have options in respect of its equity securities that, in the opinion of the Manager, are sufficiently liquid to permit the Portfolio Manager to write options in respect of such securities.

To achieve its investment objective, the Fund will invest in eight of the ten largest pharmaceuticals issuers taken from an universe of equity securities selected by the Manager of the Fund. The remaining two equity securities also come from the universe of equities selected by the Manager of the Fund. The Fund may invest in American Depository Reciepts of pharmaceutical and healthcare issuers that are not listed on a Canadian stock exchange. All other securities held by the Fund will be common shares of pharmaceutical and healthcare issuers. The Fund's excess cash will be used to increase exposure to issuers with less than the average weight of the Fund.

RISK

The risks associated with investing in the Fund are as described in the prospectus. There were no material changes to the Fund over the year ended December 31, 2024 (the "Period") that affected the overall level of risk of the Fund.

RESULTS OF OPERATIONS

Overall Performance

The Fund's return by share type compared to the MSCI Daily Total Return World Gross Pharmaceutical Local Index (USD)$^{\pm}$ for the Period is as follows:

	Return %
Class A shares	(4.64)
Preferred shares	5.09
MSCI Daily Total Return World Gross Pharmaceutical Local Index (USD)$^{\pm}$	5.89

The primary reason for the divergence is that the Fund is concentrated in only ten securities.

The Fund was invested in eight of the largest pharmaceutical issuers by market capitalization and two large capitalization biotechnology stocks listed on a North American exchange.

The Preferred shares provide their holders with a fixed cumulative preferential quarterly cash distribution in the amount of $0.125 per share (subject to net asset value minimums) and as a result of the priority of the Preferred shares, the expenses of the Company are borne by Class A shareholders. Performance of the Preferred shares is equivalent to the fixed distribution whereas the Class A shares performance is impacted by the capital appreciation (depreciation) and expenses over and above the preferential return of the Preferred shares. As a result, the performance of the Class A shares can vary significantly from the Preferred shares.

Factors Affecting Fund Results

For the Period, the Health Care sector posted positive returns, albeit lagging the broader market. The broader market was heavily skewed, in part, by strong performances in Information Technology, Communication Services and select Consumer Discretionary stocks. The sector turned out to be one of the weaker performers within the market.

Big Pharma Split Corp.

The Health Care sector and specifically the Pharmaceutical sub-sector performed well during the first half of the year and through the summer months. April through the end of August, saw a strong recovery with some volatility through August as market breadth expanded across the healthcare sectors. In the early fall, concerns surrounding potential policies from the incoming administration, coupled with negative sentiment (specifically towards companies operating within the managed care sub-sectors, such as UnitedHealth Group Incorporated) caused a pullback in select areas within the Health Care sub-sectors but also weighed on sentiment toward pharmaceutical companies.

Across the Pharmaceuticals sub-sector, clinical trial results for diabetes and weight loss treatments highlighted the potential for a very large market and benefitted the top performing position in the Fund, Eli Lilly and Company, a market leader in this therapeutic area over the course of the Period. This was driven primarily by strength in the stock during the first half of the year. On the other hand, Bristol-Myers Squibb Company saw increased competition coupled with concerns surrounding loss of exclusivity in certain drugs later in the decade that resulted in the stock performing poorly during the first half of the year. Subsequently, strong earnings and reduced fears of competition from potential competitors, resulted in the stock recovering and made it the top performing stock during the second half of the year. This highlights the benefits of diversification within the sub-sector.

The Fund sold call options on the underlying holdings during the Period to meet its investment objectives.

RECENT DEVELOPMENTS

Potential Impact for the Fund

In the shorter-term, the macro environment (both economic and geopolitical), while appearing to stabilize, continues to have some uncertainty. Inflationary pressures have subsided and expectations that central banks will continue to cut interest rates further have been a reprieve for broader markets. Nonetheless, inflationary pressures and the potential for fewer interest rate cuts, or even the potential for interest rate increases, and expectations can change quickly based on economic data.

Uncertainty surrounding potential policy changes from the new U.S. administration, including tariffs and geopolitical trade relations, remains a source of negative sentiment and risk within the market and for the Health Care sector. There is no certainty on what policy initiatives may actually be implemented by the incoming administration and this will likely continue to be a cloud overhanging broader markets through 2025.

Israel and Hamas reached an armistice that included a hostages/prisoners exchange on January 15, 2025, giving faint hope for cooling hostilities in that region to begin the year. Meanwhile, the new administration has vowed to work to end the costly war between Russia and Ukraine.

Regardless of the shorter-term macro environment, the primary long-term drivers for the Health Care sector and Pharmaceuticals sub-sector over the medium-longer term remain intact: global aging populations, developing markets, and technological innovation (both across devices and bio/pharmaceutical drugs). These medium- to longer-term drivers form the basis of our positive view on the sector. It is also well positioned to withstand some of the shorter-term macro uncertainty that may persist and remains positioned to participate in the upside recovery as the breadth of participation continues to expand across the broader markets.

2024 Market Review

For the Period, the broader U.S. equity markets recorded above average returns of more than 20%. This came on the back of the momentum from 2023, when the broader U.S. markets performed strongly. Back-to-back returns in the broader market of over 20% annually has only occurred a few times over the past 40+ years. Despite performing strongly, the U.S. markets did see some meaningful shorter-term corrections over the course of the review Period.

For the Period, the strong performance of the equity market was not uniform across sectors nor individual stocks. Information Technology and Communication Services posted the best returns of all sectors in the first six months of the Period. Within these two leading sectors, returns were highly concentrated in a few large companies. This saw market capitalization weighted indexes being heavily influenced by above average performance in a relatively small number of mega-cap stocks, particularly those perceived as beneficiaries of investment in artificial intelligence ("AI") focused infrastructure. While select large companies were a key driver of the overall market performance during the first half, owing to their strong relative performances and sizes, the breadth of participation across stocks and sectors expanded over the course of the Period with all the 11 main sectors in the U.S. posting positive returns.

In the Fixed Income market, U.S. Treasury 10-Year Bond Yields moved modestly higher early in 2024, bouncing back from over-sold conditions coming into the end of 2023. For the review Period, the fixed income market, like the equity market, was sensitive to any new data that signaled, or failed to signal, the end of the U.S. Federal Reserve (the "Fed") restrictive monetary policy. For example, in April, new data showed that inflation was still strong. This caused long-term bond yields to move higher and the equity market to pull back. In the months that immediately followed, new data showed that inflation was subsiding. This resulted in a reversal of the pullback in both the bond and equity markets.

As additional data was unveiled through the early fall, we saw stabilization across the economic data and validation through improving corporate earnings. Further, stronger earnings guidance gave rise to improved sentiment and a rebound in equities. Most notably, there was broader market participation across the various sub-sectors and within sub-sectors. Amidst the recovery in stocks and improving economic strength, there were growing inflationary metrics that triggered concerns that the Fed may reduce the number of interest rate cuts over the coming year. This put upward pressure on longer dated interest rates during this time.

Following the U.S. election results in early November, markets continued to move higher as the election results eliminated an uncertainty that had been prevalent in the market. However, that was quickly followed by rhetoric surrounding tariffs that instilled policy concerns across the market. This caused volatility in the equity markets at the end of the Period. Given the fact that many of the proposed tariff policies would likely be inflationary, this added to further speculation that inflation pressures will be forthcoming through 2025. It also served to push longer dated bond yields higher, and changed expectations for the number of Fed's cuts in interest rates expected during 2025. This caused bond prices across durations to come under pressure during the latter part of the Period.

With economic data moderating more quickly in Canada than the U.S., the Bank of Canada ("BoC") announced an interest rate cut in June. This was the first in four years, and the first G7 country to do so this economic cycle. The BoC continued to cut its overnight lending rate for a total of seven effective 0.25% cuts during the Period.

Geopolitical tensions worsened in key regions of the globe during the Period. Specifically, ongoing wars in Eastern Europe and in the Middle East were a source of headline risks during and post the end of the Period. The ongoing geopolitical tensions during the Period did provide some support to safe-haven assets such as gold and helped to keep global oil prices trading in relatively high ranges. However, the broader markets were less sensitive to the daily headlines compared to the previous years, even though these headlines remain a source of risks for them.

RELATED PARTY TRANSACTIONS AND OTHER EXPENSES

Management fees
The Fund pays the Manager a management fee calculated based on the average daily net asset value ("NAV") and paid monthly in arrears, based on an annual rate of 0.75%, plus applicable taxes, of the NAV of the Fund. For these purposes, the Preferred shares are not considered a liability of the Fund. At its sole discretion, the Manager may waive management fees or absorb expenses of the Fund. The management expense ratios of the Fund with and without the waivers and absorptions are reported in the Ratios and Supplemental Data table below.

Operating expenses
The Fund is responsible for operating expenses relating to the carrying on of its business, including custodial services, interest, taxes, legal, audit fees, transfer agency services relating to the issue and redemption of units, and the cost of financial and other reports, costs and expenses for the Fund's Independent Review Committee ("IRC"), including fees and expenses of the IRC members and compliance with applicable laws, regulations and policies. The Manager pays for such expenses on behalf of the Fund, except for certain expenses such as interest, and is then reimbursed by the Fund.

Other expenses
The Manager will be reimbursed by the Fund for all reasonable costs, expenses and liabilities incurred by the Manager for performance of services on behalf of the Fund in connection with the discharge by the Manager of its duties hereunder. Such costs and expenses may include, without limitation: mailing and printing expenses for reports to unitholders and other unitholder communications; a reasonable allocation of salaries and benefits; and other administrative expenses and costs incurred in connection with the Fund's ongoing operations. These expenses are allocated by the Manager on a reasonable basis, across all the Harvest Portfolios Group Inc. funds, and classes of each applicable fund. These expenses were $5,505 for the Period and are included in the unitholder reporting costs on the Statement of Comprehensive Income (Loss) in the financial statements.

Waivers and absorptions
At its sole discretion, the Manager may waive management fees or absorb expenses of the Fund. There were no management fee waivers or expense absorptions for the Period.

The management expense ratios of the Fund with and without the waivers and absorptions are reported in the Ratios and Supplemental Data table below.

Other transactions
Officers, directors and related entities of the Manager invest in units of the Fund from time to time in the normal course of business and on the same basis as arm's length investors. As at December 31, 2024 officers and directors did not own units of the Fund.

Issue costs
Certain Offering expenses such as costs of creating the Fund, the cost of printing and preparing the prospectus, legal expenses of the Fund, agent's fees payable by the Fund, out-of-pocket expenses incurred by the agents as well as brokerage commissions charged on trades under the ATM Program (as defined below) are included in the carrying amount of the Fund's obligation for net assets attributable to holders of redeemable Class A shares. As a result of the priority of the Preferred shares, the expenses of the Offering will effectively be borne by holders of the Class A shares (as long as the net asset value per unit exceeds the Offering price per Preferred share plus accrued and unpaid distributions) and the net asset value per Class A share will reflect the expenses of the Offering of both the Preferred shares and Class A shares.

OTHER INFORMATION

On June 7, 2021, the Fund announced commencement of an at-the-market equity program (the "ATM Program") which allows the Fund to issue shares to the public from time to time, at the Fund's discretion. Any Class A shares or Preferred shares sold in the ATM Program will be sold through the Toronto Stock Exchange or any other marketplace in Canada on which the Class A shares and Preferred shares are listed, quoted or otherwise traded at the prevailing market price at the time of sale. The inital ATM Program expired on December 4, 2022 and was subsequently renewed December 7, 2022 with an expiry date of January 7, 2025. Following the expiration of this secondary ATM Program in 2025, it was again renewed on January 13, 2025.

During the the Period, 26,806 Class A shares were issued under the ATM Program at an average selling price of $13.11 per Class A share. Gross proceeds, net proceeds and commissions on the Class A shares issued were $351,326, $342,576 and $8,751, respectively.

During the the Period, 158,900 Preferred shares were issued under the ATM Program at an average selling price of $10.05 per Preferred share. Gross proceeds, net proceeds and commissions on the Preferred shares issued were $1,596,945, $1,589,000 and $7,945, respectively.

On February 15, 2023, the Fund entered into an agreement with an agent to purchase the Fund's Class A shares for cancellation on the Toronto Stock Exchange. The Fund can purchase for cancellation a maximum of 293,494 Class A shares at the prevailing market price but at a price not greater than the most recent net asset value per share calculated prior to the repurchase.

During the the Period, 1,700 Class A shares were cancelled under the agreement at an average purchase price of $14.39 per Class A share. Gross proceeds, net proceeds and commissions on the Class A shares cancelled were $24,462, $24,462 and $0, respectively.

RECOMMENDATIONS OR REPORTS BY THE INDEPENDENT REVIEW COMMITTEE

The IRC tabled no special reports and made no extraordinary material recommendations to management of the Fund during the Period.

Big Pharma Split Corp.

FINANCIAL HIGHLIGHTS

The following tables present selected key financial information about the Class A shares of the Fund or the Fund and are intended to help you understand the Fund's financial performance for the Period and past annual periods. This information is derived from the Fund's annual audited financial statements.

THE FUND'S NET ASSETS PER UNIT		2024		2023		2022		2021		2020
Net assets - beginning of the period	**$**	**13.62**	**$**	**15.40**	**$**	**15.07**	**$**	**14.11**	**$**	**15.41**
Increase (decrease) from operations										
Total revenue		0.59		0.56		0.60		0.59		0.83
Total expenses		(0.46)		(0.47)		(0.45)		(0.49)		(0.42)
Preferred share distribution		(0.48)		(0.42)		(0.50)		(0.53)		(0.48)
Preferred shares agent fees and issue costs		(0.01)		-		-		(0.15)		-
Premium (discount) on issuance of preferred shares		0.01		-		-		0.18		-
Realized gains (losses) for the period		1.02		2.07		2.00		(0.01)		2.21
Unrealized gains (losses) for the period		(1.14)		(2.27)		(0.07)		3.68		(2.36)
Total increase (decrease) from operations[1]	**$**	**(0.47)**	**$**	**(0.53)**	**$**	**1.58**	**$**	**3.27**	**$**	**(0.22)**
Distributions[2]										
Dividends		(0.21)		(0.21)		(0.93)		(0.21)		(1.24)
Capital gains		(1.10)		(1.03)		(0.31)		(1.75)		-
Total annual distributions[2]	**$**	**(1.31)**	**$**	**(1.24)**	**$**	**(1.24)**	**$**	**(1.96)**	**$**	**(1.24)**
Net assets - end of period[1]	**$**	**11.82**	**$**	**13.62**	**$**	**15.40**	**$**	**15.07**	**$**	**14.11**

RATIOS AND SUPPLEMENTAL DATA		2024		2023		2022		2021		2020
Total net asset value (including Preferred shares) (000's)	**$**	**25,256**	**$**	**26,148**	**$**	**29,585**	**$**	**37,267**	**$**	**22,533**
Total net asset value - Class A shares (000's)	**$**	**13,683**	**$**	**15,851**	**$**	**19,731**	**$**	**22,404**	**$**	**13,185**
Number of Class A shares outstanding (000's)		1,157		1,164		1,281		1,486		935
Management expense ratio[3] - Class A shares		6.57%		6.04%		6.08%		8.36%		6.28%
Management expense ratio before waivers or absorptions[3] - Class A shares		6.57%		6.04%		6.08%		8.36%		6.28%
Trading expense ratio[4]		0.14%		0.12%		0.15%		0.15%		0.17%
Portfolio turnover rate[5]		29.87%		27.26%		26.24%		31.33%		45.91%
Net asset value per unit[6]	**$**	**21.82**	**$**	**23.84**	**$**	**26.11**	**$**	**25.07**	**$**	**24.11**
Net asset value per Class A share	**$**	**11.82**	**$**	**13.62**	**$**	**15.40**	**$**	**15.07**	**$**	**14.11**
Net asset value per Preferred share	**$**	**10.00**	**$**	**10.00**	**$**	**10.00**	**$**	**10.00**	**$**	**10.00**
Closing market price - Class A shares	**$**	**13.01**	**$**	**13.75**	**$**	**14.58**	**$**	**14.67**	**$**	**13.40**
Closing market price - Preferred shares	**$**	**10.05**	**$**	**9.70**	**$**	**9.89**	**$**	**10.60**	**$**	**10.68**

Explanatory Notes:

1. Net assets and distributions are based on the actual number of units outstanding at the relevant time. The increase (decrease) from operations is based on the weighted average number of units outstanding over the reporting period. It is not intended that the Fund's net assets per unit table act as a continuity of opening and closing net assets per Class A share.

2. Distributions, if any, are paid in cash.

3. Management expense ratio ("MER") is based on total expenses (excluding commissions and other portfolio transaction costs) of the stated period and is expressed as an annualized percentage of the Class A daily average net asset value during the period.

   The Class A MER for the year ended December 31, 2020 excluding the Preferred share distribution was 2.80%. The MER based on the daily average of the total net asset value (included Preferred shares) was 3.65%. This MER excluding the Preferred share distribution was 1.63%.

   The Class A MER for the year ended December 31, 2021 includes agent fees of $359,681, issue costs of $119,421, accretion of premium on issuance of Preferred shares of $231,526 and Preferred share distributions of $687,381. Agent fees and issue costs and accretion of premium are treated as one-time expenses and therefore were not annualized. The MER without these amounts and excluding the Preferred share distribution was 3.26%. The MER without agent fees, issue costs and accretion of premium but including the Preferred share distribution expense was 7.01%. The MER based on the daily average of the total net asset value (including Preferred shares) was 4.91%. This MER includes agent fees, issue costs, accretion of premium on issuance of Preferred shares and Preferred share distribution. This MER without these costs and excluding the Preferred share distribution was 1.91%. This MER without agent fees, issue costs and accretion of premium but including the Preferred share distribution was 4.12%.

   The Class A MER for the year ended December 31, 2022 includes agent fees of $nil, issue costs of $6,520, accretion of premium on issuance of Preferred shares of $4,155 and Preferred share distributions of $756,020. Agent fees and issue costs and accretion of premium are treated as one-time expenses and therefore were not annualized. The MER without these amounts and excluding the Preferred share distribution was 2.76%. The MER without agent fees, issue costs and accretion of premium but including the Preferred share distribution expense was 6.07%. The MER based on the daily average of the total net asset value (including Preferred shares) was 3.68%. This MER includes agent fees, issue costs, accretion of premium on issuance of Preferred shares and Preferred share distribution. This MER without these costs and excluding the Preferred share distribution was 1.67%. This MER without agent fees, issue costs and accretion of premium but including the Preferred share distribution was 3.67%.

The Class A MER for the year ended December 31, 2023 includes agent fees of $nil, issue costs of $2,120, accretion of premium on issuance of Preferred shares of $2,120 and Preferred share distributions of $505,670. Agent fees and issue costs and accretion of premium are treated as one-time expenses and therefore were not annualized. The MER without these amounts and excluding the Preferred share distribution was 3.13%. The MER without agent fees, issue costs and accretion of premium but including the Preferred share distribution expense was 6.04%. The MER based on the daily average of the total net asset value (including Preferred shares) was 3.82%. This MER includes agent fees, issue costs, accretion of premium on issuance of Preferred shares and Preferred share distribution. This MER without these costs and excluding the Preferred share distribution was 1.98%. This MER without agent fees, issue costs and accretion of premium but including the Preferred share distribution was 3.82%.

The Class A MER for the Period ended December 31, 2024 includes agent fees of $nil, issue costs of $16,696, accretion of premium on issuance of Preferred shares of $7,945 and Preferred share distributions of $552,032. Agent fees and issue costs and accretion of premium are treated as one-time expenses and therefore were not annualized. The MER without these amounts and excluding the Preferred share distribution was 3.08%. The MER without agent fees, issue costs and accretion of premium but including the Preferred share distribution expense was 6.52%. The MER based on the daily average of the total net asset value (including Preferred shares) was 3.92%. This MER includes agent fees, issue costs, accretion of premium on issuance of Preferred shares and Preferred share distribution. This MER without these costs and excluding the Preferred share distribution was 1.84%. This MER without agent fees, issue costs and accretion of premium but including the Preferred share distribution was 3.89%.

4. The trading expense ratio represents total commissions and other portfolio transaction costs expressed as an annualized percentage of daily average net asset value during the period. In 2020 the calculation was modified to include certain transaction costs charged by the custodian. The trading expense ratio in prior periods was not re-stated.

5. The Fund’s portfolio turnover rate indicates how actively the Fund’s portfolio advisor manages its portfolio investments. A portfolio turnover of 100% is equivalent to the Fund buying and selling all of the securities in its portfolio once in the course of the period. The higher a Fund’s portfolio turnover rate, the greater the trading costs payable by the Fund and the greater the chance of an investor receiving taxable capital gains. There is not necessarily a relationship between a high turnover rate and the performance of a Fund.

6. Net asset value per unit as of the financial statement date is calculated by adding the net assets attributable to Class A shares and the redemption value of the Preferred shares and dividing the total by the average number of Class A and Preferred shares outstanding.

Big Pharma Split Corp.

PAST PERFORMANCE

The performance information presented herein assumes all dividends of the Fund during the periods presented were reinvested in additional securities of the Fund. The performance information does not take into account sales, redemptions, or other charges that would have reduced returns or affected performance. Past performance of the Fund is not necessarily indicative of how it will perform in the future.

Year-by-Year Returns
The following charts present the Fund's performance for each of the years shown and illustrate how the Fund's performance varied for Class A and Preferred shares. The chart shows, in percentage terms, how much an investment made on the first day of each financial year would have grown or decreased by the last day of each financial year.

Class A shares



2017 represents the period from November 24 to December 31

Preferred shares



2017 represents the period from November 24 to December 31

Big Pharma Split Corp.

Annual Compound Returns
The following table shows the annual compound returns for the Fund. All returns are in Canadian dollars, unless otherwise specified, on a total return basis, net of fees.

For comparison purposes, the MSCI Daily Total Return World Gross Pharmaceutical Local Index (USD)± is used. While the Fund uses this benchmark for long-term performance comparisons, it is not managed relative to the composition of this benchmark. As a result, the Fund may experience periods when its performance is not aligned with this benchmark, either positively or negatively. The return of this benchmark is calculated without the deduction of management fees and fund expenses whereas the performance of the Fund is calculated after deducting such fees and expenses. Please see the "Results of Operations" section of this report for a discussion on recent performance.

Investment Return %	1 Year	3 Years	5 Years	10 Years	Since Inception‡
Fund Performance Class A shares	-4.64	0.72	4.75	-	7.92
MSCI Daily Total Return World Gross Pharmaceutical Local Index (USD)±	5.89	5.55	7.85	-	9.04
Fund Performance Preferred shares	5.09	5.09	5.09	-	5.10
MSCI Daily Total Return World Gross Pharmaceutical Local Index (USD)±	5.89	5.55	7.85	-	9.04

‡ Since inception dates are: Class A shares – November 24, 2017; Preferred shares – November 24, 2017

Big Pharma Split Corp.

SUMMARY OF INVESTMENT PORTFOLIO

The major portfolio categories and top holdings of the Fund at the end of the Period are indicated in the following tables. A detailed breakdown of the Fund's holdings is available in the ''Schedule of Investments'' section of the Fund's annual audited financial statements.

As at December 31, 2024

Top Holdings	% of Net Asset Value
Pfizer Inc.	19.8
AbbVie Inc.	19.6
Johnson & Johnson	19.4
Sanofi ADR	18.9
Merck & Co., Inc.	18.6
Eli Lilly and Company	17.9
Amgen Inc.	17.8
AstraZeneca PLC ADR	17.7
GSK PLC ADR	17.4
Bristol-Myers Squibb Company	16.9
Cash and other assets and liabilities	6.3
Options	(0.2)
Foreign currency forward contracts	(5.5)
Preferred shares	(84.6)
Total	**100.0**

This summary of investment portfolio may change due to the ongoing portfolio transactions of the Fund. Quarterly updates of the Fund's investment portfolio are available at **www.harvestetfs.com**.

SECTOR ALLOCATION

Sector	% of Net Asset Value
Health Care	184.0
Cash and other assets and liabilities	6.3
Options	(0.2)
Foreign currency forward contracts	(5.5)
Preferred shares	(84.6)
Total	**100.0**

GEOGRAPHIC ALLOCATION

Country of Risk	% of Net Asset Value
United States	147.4
France	18.9
United Kingdom	17.7
Cash and other assets and liabilities	6.3
Options	(0.2)
Foreign currency forward contracts	(5.5)
Preferred shares	(84.6)
Total	**100.0**

Big Pharma Split Corp.

Disclaimers

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This document may contain forward-looking statements relating to anticipated future events, results, circumstances, performance or expectations that are not historical facts but instead represent our beliefs regarding future events. By their nature, forward-looking statements require us to make assumptions and are subject to inherent risks and uncertainties. There is significant risk that predictions and other forward-looking statements will not prove to be accurate. We caution readers of this document not to place undue reliance on our forward-looking statements as a number of factors could cause actual future results, conditions, actions or events to differ materially from the targets, expectations, estimates or intentions expressed or implied in the forward-looking statements. Actual results may differ materially from management expectations as projected in such forward-looking statements for a variety of reasons, including but not limited to market and general economic conditions, interest rates, regulatory and statutory developments, the effects of competition in the geographic and business areas in which the Fund may invest and the risks detailed from time to time in the Fund's prospectus or offering memorandum. We caution that the foregoing list of factors is not exhaustive and that when relying on forward-looking statements to make decisions with respect to investing in a Fund, investors and others should carefully consider these factors, as well as other uncertainties and potential events, and the inherent uncertainty of forward-looking statements. Due to the potential impact of these factors, the Fund does not undertake, and specifically disclaims, any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by applicable law.

± Source: MSCI. Certain information contained herein (the "Information") is sourced from/copyright of MSCI Inc., MSCI ESG Research LLC, or their affiliates ("MSCI"), or information providers (together the "MSCI Parties") and may have been used to calculate scores, signals, or other indicators. The Information is for internal use only and may not be reproduced or disseminated in whole or part without prior written permission. The Information may not be used for, nor does it constitute, an offer to buy or sell, or a promotion or recommendation of, any security, financial instrument or product, trading strategy, or index, nor should it be taken as an indication or guarantee of any future performance. Some funds may be based on or linked to MSCI indexes, and MSCI may be compensated based on the fund's assets under management or other measures. MSCI has established an information barrier between index research and certain Information. None of the Information in and of itself can be used to determine which securities to buy or sell or when to buy or sell them. The Information is provided "as is" and the user assumes the entire risk of any use it may make or permit to be made of the Information. No MSCI Party warrants or guarantees the originality, accuracy and/or completeness of the Information and each expressly disclaims all express or implied warranties. No MSCI Party shall have any liability for any errors or omissions in connection with any Information herein, or any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.

Harvest
PORTFOLIOS GROUP

Head Office

610 Chartwell Rd, Suite 204 Oakville, Ontario L6J 4A5
Phone Number: 416.649.4541
Toll Free: 866.998.8298
Fax Number: 416.649.4542
Email: info@harvestportfolios.com

harvestportfolios.com